What Did We Learn from the TRIUMPH-4 Phase 3 Study on Retatrutide?
Research & Educational Review
A mechanism-first, compliance-safe summary of publicly released Phase 3 outcomes in obesity + knee osteoarthritis.
Research Use Only Disclaimer
This article is provided for educational and informational purposes only. It summarizes publicly available clinical trial information and discusses theoretical research mechanisms. It does not constitute medical advice, diagnosis, or treatment guidance. It is not affiliated with, sponsored by, or endorsed by Eli Lilly and Company or any pharmaceutical manufacturer. Nothing in this article should be interpreted as promoting the use of any drug or compound for human or animal use.
For more on how we write research-first content, see: Why Peptide Bioavailability Isn’t What You Think.
Quick Takeaways
- TRIUMPH-4 (Phase 3) reported mean weight loss up to ~28.7% (about ~71.2 lbs) at 68 weeks in adults with obesity and knee osteoarthritis.
- Knee osteoarthritis outcomes improved substantially: WOMAC pain reductions reported up to ~75.8% in topline reporting.
- Secondary measures (blood pressure, lipids, inflammation markers) generally moved in favorable directions in sponsor summaries and media analyses.
- Side effects were largely consistent with incretin-class expectations (GI events); discontinuations due to adverse events were higher than placebo in sponsor reporting.
If you’re comparing incretin-pathway research broadly, see our: Semaglutide vs Tirzepatide vs Retatrutide (Research Comparison).
TRIUMPH-4: What It Studied
TRIUMPH-4 is a Phase 3, randomized, placebo-controlled study evaluating once-weekly retatrutide (LY3437943) in adults with obesity or overweight and knee osteoarthritis. A distinctive feature of this trial is its emphasis on both: body weight change and patient-reported knee pain/functional outcomes.
Trial registry listing (identifier): NCT05931367. View registry entry: ClinicalTrials.gov — TRIUMPH-4 (NCT05931367).
Key Finding #1: Weight Loss Magnitude Reached Historic Levels
The headline TRIUMPH-4 result is the reported depth of average weight loss at 68 weeks, with topline summaries noting up to ~28.7% mean reduction (about ~32.3 kg / ~71.2 lbs) at higher-dose arms in this population.
Research Context: Why “Magnitude” Matters
In metabolic research, “how much” weight changes can influence more than scale readings—it can shift downstream mechanical loading, adipokine signaling, and inflammatory tone. That’s one reason TRIUMPH-4’s combined focus (weight + osteoarthritis outcomes) drew attention.
For background on how “pathway-first” thinking can matter more than mg-first thinking, see: The Myth of mg-Dosing & the Rise of Receptor-First Science.
Key Finding #2: Substantial Improvements in Knee Pain & Physical Function
TRIUMPH-4 measured osteoarthritis outcomes using the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index), a widely used patient-reported instrument for osteoarthritis pain and function. Public reporting highlighted improvements in: pain and physical function.
- WOMAC pain: topline reporting noted reductions up to ~4.5 points (reported as ~75.8% change).
- Function: key secondary endpoints included improvements in physical function alongside pain outcomes.
Important research nuance: These outcomes do not necessarily establish “disease modification” of osteoarthritis. They are consistent with a hypothesis that major reductions in mass and metabolic load can influence symptoms via: mechanical unloading, inflammatory signaling shifts, and pain-perception pathways.
If you want deeper “systems thinking” content, you may also like: How Environmental Stress Changes Peptide Responsiveness.
Key Finding #3: Cardiometabolic Markers Moved in Favorable Directions
Public summaries and trial reporting commentary described improvements across several metabolic risk markers in TRIUMPH-4, including blood pressure and lipid-related measures. While TRIUMPH-4 is not a dedicated cardiovascular outcomes trial, these secondary marker shifts are often tracked in obesity pharmacology research for hypothesis-building.
If you’re building a “beyond weight loss” knowledge base, consider linking this with: HPLC & MS Analysis: How to Read COAs (What to Look For) — because trial-grade discussions only matter if your research analytics are solid.
Key Finding #4: Safety & Tolerability Looked Like Potent Incretin-Class Signaling
In sponsor medical summaries and public reporting, the most commonly noted adverse events were gastrointestinal in nature (e.g., nausea, diarrhea, constipation, vomiting), consistent with incretin-pathway pharmacology.
Discontinuations (Public Sponsor Reporting)
Public sponsor materials reported that discontinuations due to adverse events were higher in treatment arms versus placebo (for example, discontinuation rates due to adverse events reported as 12.2% and 18.2% in certain treatment arms vs 4.0% for placebo in topline sponsor reporting).
Why This Matters (Research Lens)
Potency often correlates with a narrower tolerability window. In research discussions, this is where concepts like receptor sensitivity, signal “load,” and adaptive response become relevant—especially when comparing single-agonist, dual-agonist, and triple-agonist designs.
Related reading: Receptor (Research Concepts).
Why Triple-Agonist Signaling Is the Bigger Story
Retatrutide is commonly described as a “triple agonist,” meaning it targets three metabolic hormone receptors: GLP-1, GIP, and the glucagon receptor. In research terms, the rationale is that combining appetite regulation (GLP-1), nutrient partitioning/adipocyte signaling (GIP), and energy expenditure pathways (glucagon signaling) may create a broader systems-level metabolic effect than any single pathway alone.
What TRIUMPH-4 Does Not Answer Yet
Even with strong topline results, there are important open questions that require longer follow-up and additional Phase 3 readouts:
- Durability: How stable are outcomes beyond ~68 weeks?
- Comparative positioning: How do head-to-head comparisons (if conducted) change interpretation?
- Broader outcomes: Which comorbidities show consistent signal across the full TRIUMPH program?
- Tolerability strategy: What dosing/escalation approaches best balance effect size and discontinuation risk? (We do not provide dosing guidance.)
References (Direct Links)
- Eli Lilly investor release / press statement (TRIUMPH-4 topline results):
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average - PR Newswire distribution of the same release (convenient mirror):
https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html - ClinicalTrials.gov registry entry (TRIUMPH-4 / NCT05931367):
https://clinicaltrials.gov/study/NCT05931367 - Patient Care Online summary (weight loss + WOMAC pain reporting):
https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial - Pharmacy Times summary (trial outcomes overview):
https://www.pharmacytimes.com/view/once-weekly-retatrutide-reduces-weight-and-knee-pain-in-patients-with-obesity-and-osteoarthritis - Lilly Medical information page (common adverse events table in public view):
https://medical.lilly.com/us/products/answers/what-are-the-preliminary-results-with-retatrutide-from-triumph-4-in-participants-with-obesity-or-overweight-and-osteoarthritis-306723
